Physician profile
Stephen D Silberstein
NPI 1881617413
$428,329.40
in general payments reported to CMS, 2019-2025
37 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246K · 2020: $77K · 2021: $49K · 2022: $12K · 2023: $25K · 2024: $6,673 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Food and Beverage: $1,814 · Honoraria: $1,200 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,072.50 |
| Food and Beverage | $1,813.65 |
| Honoraria | $1,200.00 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $120,869.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $77,133.41 | 2019-2023 | Austedo Xr, Ajovy |
| Allergan, INC. | $73,855.67 | 2019-2021 | |
| Lilly USA, LLC | $59,296.78 | 2019-2023 | Emgality |
| Medical Device Business Services, INC. | $24,612.50 | 2023-2025 | Trufill |
| Abbvie INC. | $16,935.57 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Amgen INC. | $13,561.42 | 2019-2023 | Aimovig |
| Biodelivery Sciences International, INC. | $8,911.40 | 2021 | |
| Impel Pharmaceuticals INC. | $7,451.08 | 2022-2023 | Trudhesa |
| Lundbeck LLC | $7,125.00 | 2020-2022 | |
| Ipsen Pharma Sas | $4,260.00 | 2023 | Dysport |
| Merck Sharp & Dohme LLC | $3,850.00 | 2020-2025 | |
| Ipsen Innovation | $3,510.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $2,400.00 | 2023-2024 | Elyxyb |
| Otsuka Pharmaceutical Co., Ltd. | $1,500.00 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upjohn US 1 LLC | $1,000.00 | 2019 | |
| Biogen, INC. | $836.06 | 2022 | |
| Pfizer INC. | $247.04 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $247.03 | 2019-2020 | |
| Eli Lilly and Company | $100.00 | 2021 | |
| Upsher-Smith Laboratories LLC | $85.88 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.75 | 2023 | Relistor |
| Assertio Therapeutics, INC. | $71.47 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $53.04 | 2022 | |
| Spr Therapeutics, INC | $52.08 | 2019 | |
| Grt US Holding, INC. | $49.58 | 2022 | |
| Amneal Pharmaceuticals LLC | $47.29 | 2019-2020 | |
| Tonix Medicines, INC. | $34.94 | 2023 | |
| Dr.Reddy'S Laboratories,INC. | $26.64 | 2019 | |
| Vertical Pharmaceuticals, LLC | $26.38 | 2019 | |
| Electronic Waveform Lab, INC. | $21.79 | 2019 | |
| Eisai INC. | $18.81 | 2023 | |
| Currax Pharmaceuticals LLC | $16.63 | 2020 | |
| Promius Pharma LLC | $16.35 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.40 | 2019 | |
| Zyla Life Sciences, INC. | $12.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Silberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.